New malaria combo shows promise in clearing parasites
NCT ID NCT07235033
First seen Nov 19, 2025 · Last updated May 15, 2026 · Updated 14 times
Summary
This study tested a combination of two anti-malarial drugs, cipargamin and KLU156, in 60 people aged 12 and older with uncomplicated Plasmodium falciparum malaria. The main goal was to see if the drugs could clear the malaria parasite from the blood by day 29 without the infection coming back. The study is now complete and provides information on how well the treatment works and its safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Abidjan, 13BP972, Côte d’Ivoire
-
Novartis Investigative Site
Libreville, BP 1437, Gabon
-
Novartis Investigative Site
Ahero, 40100, Kenya
Conditions
Explore the condition pages connected to this study.